fludeoxyglucose f-18
Approved
Aug 19, 1994
Fludeoxyglucose F-18 is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. — NCATS
Clinical trial activity
372 trials · 248 clinical orgs · 44 marketing orgs
Earliest trial started Dec 1, 1996 (NCT00002930)
Timeline
1990s
- Aug 19, 1994
State University of New York, Brooklyn — Earliest FDA Approval
- Aug 19, 1994
State University of New York, Brooklyn — NDA Secondary Org
- Aug 19, 1994
State University of New York, Brooklyn — NDA Organization
- Jan 1, 1996
Cornell University — Earliest Phase 2 Sponsor(trial)
- Jan 1, 1997
Cornell University — Earliest Phase 1 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
2000s
- Aug 5, 2004
Cornell University — NDA Secondary Org
- Aug 19, 2005
Feinstein Institute for Medical Research — NDA Secondary Org
2010s
- Feb 25, 2011
Siemens — Marketing Organization
- Feb 14, 2013
Houston Cyclotron — Marketing Organization
- Jun 27, 2013
University of California, Los Angeles — Marketing Organization
- Dec 23, 2013
University of Wisconsin — Marketing Organization
- Jan 13, 2014
University of Texas at Houston — Marketing Organization
- Feb 4, 2014
Lantheus Medical Imaging — Marketing Organization
- Feb 4, 2014
Pharmalogic Hldgs — Marketing Organization
- Feb 5, 2014
Essential Isotopes, LLC — Marketing Organization
- Feb 5, 2014
Washington University in St. Louis — Marketing Organization
- May 9, 2014
University of California, San Francisco — Marketing Organization
- Aug 6, 2014
University of Iowa — Marketing Organization
- Sep 25, 2014
Harvard University — Marketing Organization
- Oct 21, 2014
Zevacor — Marketing Organization
- Oct 21, 2014
Decatur Memorial Hospital — Marketing Organization
- Oct 29, 2014
CPDC — Marketing Organization
- Oct 29, 2014
University of Pennsylvania — Marketing Organization
- Oct 29, 2014
Isologic Innovative — Marketing Organization
- Oct 30, 2014
Hot Shots Nuclear Medicine — Marketing Organization
- Dec 18, 2014
Shertech Labs Llc — Marketing Organization
- Jan 7, 2015
NCM USA — Marketing Organization
- Feb 4, 2015
Northland Nuclear Medicine — Marketing Organization
- Apr 7, 2015
Precision Nuclear — Marketing Organization
- Apr 22, 2015
Spectron Mrc Llc — Marketing Organization
- Apr 22, 2015
Nukemed — Marketing Organization
- Apr 23, 2015
Methodist Cancer Center, Houston, Texas — Marketing Organization
- May 1, 2015
Biomedical Research Foundation — Marketing Organization
- Jun 23, 2015
Jubilant DraxImage Inc. — Marketing Organization
- Jun 23, 2015
University of Utah — Marketing Organization
- Jun 23, 2015
Jubilant Innovation Ltd. — Marketing Organization
- Jul 17, 2015
University of Michigan — Marketing Organization
- Aug 31, 2015
Queen Hamamatsu Pet Imaging Center — Marketing Organization
- Aug 31, 2015
Sofie — Marketing Organization
- Sep 11, 2015
Stanford University — Marketing Organization
- Oct 27, 2015
Kettering Health Network — Marketing Organization
- Oct 30, 2015
3d Imaging Drug Design & Development — Marketing Organization
- Nov 13, 2015
Cardinal Health — Marketing Organization
- Nov 19, 2015
Midwest Medical Isotopes — Marketing Organization
- Apr 11, 2016
Columbia University — Marketing Organization
- Dec 8, 2016
Memorial Sloan-Kettering Cancer Center — Marketing Organization
2020s
- Feb 6, 2020
The University of Texas, Dallas — Marketing Organization
- Dec 16, 2020
University of Southern California — Marketing Organization
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2
- Adrenal Gland Neoplasms · Phase 3
- Alcohol Drinking · Phase 2/Phase 3
- Alcohol-Induced Disorders · Phase 2/Phase 3
- Alzheimer Disease · Phase 4
- Anus Neoplasms · Phase 2
- Aortic Aneurysm, Abdominal · Phase 4
- Aphasia · Phase 1
- Aphasia, Primary Progressive · Phase 1
- Arteries · Phase 1
- Arthritis, Rheumatoid · Phase 1
- Asthma · Phase 4
- Astrocytoma · Phase 2
- Atherosclerosis · Phase 2
- Autoimmune Diseases · Phase 1
- Basal Cell Carcinoma · Phase 1/Phase 2
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 4
- Breast Neoplasms, Male · Phase 1/Phase 2
- Burkitt Lymphoma · Phase 2
- Carcinoma · Early Phase 1
- Carcinoma, Adenoid Cystic · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Mucoepidermoid · Phase 1/Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 3
- Carcinoma, Transitional Cell · Phase 1
- Carcinoma, Verrucous · Phase 1
- Cardiovascular Diseases · Early Phase 1
- Carotid Stenosis · Phase 4
- Cholangiocarcinoma · Phase 2
- Chordoma · Phase 1/Phase 2
- Chronic Pain · Phase 1
- Cigarette Smoking · Phase 2
- Cognitive Dysfunction · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Craniopharyngioma · Phase 2
- Crohn Disease · Phase 4
- Cushing Syndrome · Phase 1/Phase 2
- Cystic Fibrosis · Phase 3
- Dementia, Vascular · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diagnostic Imaging · Phase 2
- Diagnostic Techniques and Procedures · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Endocrine System Diseases · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Ependymoma · Phase 2
- Epidermal Growth Factor · Phase 2
- Esophageal Neoplasms · Phase 2/Phase 3
- Frontotemporal Dementia · Phase 4
- Giant Cell Arteritis · Phase 2
- Glioblastoma · Phase 2
- Glioma · Phase 2
- Gliosarcoma · Phase 1/Phase 2
- Granuloma · Phase 1/Phase 2
- Hamartoma · Phase 1
- Hamartoma Syndrome, Multiple · Phase 2
- Head and Neck Neoplasms · Phase 3
- Healthy Volunteers · Phase 2
- Heart Diseases · Phase 4
- Heart Valves · Phase 4
- Histiocytosis · Phase 3
- Hodgkin Disease · Phase 3
- Hyperparathyroidism, Primary · Phase 2
- Hypersensitivity · Phase 1
- Hypertension, Pulmonary · Phase 2
- Hypertrophy, Left Ventricular · Phase 2
- Hypopharyngeal Neoplasms · Phase 1/Phase 2
- Idiopathic Pulmonary Fibrosis · Phase 1
- Iliac Artery · Phase 1
- Inflammatory Breast Neoplasms · Early Phase 1
- Intermittent Claudication · Phase 1
- Ischemic Attack, Transient · Phase 4
- Joint Prosthesis · Phase 2
- Kidney Neoplasms · Phase 2
- Laryngeal Neoplasms · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lewy Body Disease · Phase 4
- Liver Diseases · Phase 3
- Liver Neoplasms · Phase 2
- Lung Diseases · Phase 2
- Lung Neoplasms · Phase 4
- Lymphoma · Phase 3
- Lymphoma, B-Cell · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 3
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 3
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Phase 2
- Mass Screening · Phase 2
- Medulloblastoma · Phase 2
- Melanoma · Phase 2
- Meningioma · Early Phase 1
- Mesothelioma · Phase 2
- Monoclonal Gammopathy of Undetermined Significance · Phase 2
- Mouth Neoplasms · Phase 1/Phase 2
- Multiple Myeloma · Phase 3
- Multiple Pulmonary Nodules · Phase 2
- Multiple Sclerosis · Phase 4
- Mutation · Phase 2
- Mycosis Fungoides · Phase 1
- Myocardial Infarction · Early Phase 1
- Myocardial Ischemia · Phase 4
- Myofascial Pain Syndromes · Early Phase 1
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Nasopharyngeal Neoplasms · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 4
- Neovascularization, Pathologic · Phase 1
- Neuroblastoma · Phase 1/Phase 2
- Neuroendocrine Tumors · Phase 2
- Neuroimaging · Phase 4
- Nicotiana · Phase 2
- Oligodendroglioma · Phase 2
- Oropharyngeal Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Papilloma, Inverted · Phase 1/Phase 2
- Paraganglioma · Phase 2
- Parkinson Disease · Phase 2
- Penile Neoplasms · Phase 1
- Peripheral Arterial Disease · Phase 1
- Persistent Vegetative State · Early Phase 1
- Pheochromocytoma · Phase 2
- Physiology · Early Phase 1
- Pituitary Neoplasms · Phase 1
- Pleural Effusion, Malignant · Phase 2
- Pleural Neoplasms · Phase 1
- Positron-Emission Tomography · Early Phase 1
- Primary Progressive Nonfluent Aphasia · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Pulmonary Embolism · Phase 2
- Pulmonary Fibrosis · Phase 1
- Rectal Neoplasms · Phase 2
- Rhabdoid Tumor · Phase 1/Phase 2
- Salivary Gland Neoplasms · Phase 1/Phase 2
- Sarcoidosis · Phase 2
- Sarcoma · Phase 2/Phase 3
- Sarcoma, Ewing · Phase 2/Phase 3
- Sepsis · Phase 3
- Skin Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 3
- Smoldering Multiple Myeloma · Phase 2
- Solitary Fibrous Tumors · Phase 1
- Solitary Pulmonary Nodule · Phase 2
- Speech Disorders · Phase 1
- Spinal Cord Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Stroke · Phase 4
- Temporomandibular Joint · Phase 2
- Testicular Neoplasms · Phase 1
- Thyroid Carcinoma, Anaplastic · Phase 2
- Thyroid Neoplasms · Phase 2
- Tomography · Phase 4
- Tongue Neoplasms · Phase 1/Phase 2
- Tuberculosis · Phase 1/Phase 2
- Tuberculosis, Pulmonary · Phase 1
- Tumor Suppressor Protein p53 · Phase 2
- Urethral Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2/Phase 3
- Vaginal Neoplasms · Phase 2
- Vascular Calcification · Phase 1
- Venous Thromboembolism · Phase 2
- Venous Thrombosis · Phase 2
- von Hippel-Lindau Disease · Phase 2
- Vulvar Neoplasms · Phase 2
- Whole Body Imaging · Phase 4
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedPriority reviewAug 19, 1994
Chemistry & pharmacology
SMILES
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O- Mol. weight
- 182.15 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1235932 ↗
- WikipediaFludeoxyglucose (18F) ↗
- NCATS0Z5B2CJX4D ↗
- ChEMBLCHEMBL497613 ↗
- ChEMBLCHEMBL1086863 ↗
- ChEMBLCHEMBL1092067 ↗
- ChEMBLCHEMBL2068864 ↗
- ChEMBLCHEMBL2030434 ↗
Also known as
- 18f
- 18f-deoxy glucose
- 18fdg
- 18fdg
- (18f)-fdg
- (18f)-fdg
- 18-f fdg
- 18-f fdg
- 18f fdg
- 18f fdg
- 18f fdg
- 18f fdg
- 18f-fdg
- 18f-fdg
- 18f-fdg
- 18f fludeoxyglucose
- 18f fluoro-2-deoxy-2-d-glucose
- 18f fluoro-2-deoxy-2-d-glucose
- 18f-fluoro-2-deoxy-d-glucose
- 18f-fluoro-2-deoxy-d-lucose
- 18f fluoro-deoxi-glucose
- 18f fluorodeoxyglucose
- 18f fluorodeoxyglucose
- 18f-fluorodeoxyglucose
- 18f-fluorodeoxyglucose
- 18f fluoroglucose
- 18f-flurodeoxyglucose
- 2-deoxy-2 [f-18] fluoro-2-d-glucose
- 2-deoxy-2 [f-18] fluoro-2-d-glucose
- 2-fluoro-2-deoxyglucose
- 2-fluoro-2-deoxyglucose
- f-18 fluorodeoxyglucose
- fdg
- fdg
- fludeoxyglucose
- fludeoxyglucose
- fludeoxyglucose
- fludeoxyglucose (18f)
- fludeoxyglucose (18f)
- fludeoxyglucose (18f)
- fludeoxyglucose (18f)
- fludeoxyglucose (18f)
- fludeoxyglucose f 18
- fludeoxyglucose f 18
- fludeoxyglucose f 18
- fludeoxyglucose f-18
- fludeoxyglucose f-18
- fludeoxyglucose f-18
- fludeoxyglucose f-18
- fludeoxyglucose f-18
- fludeoxyglucose f-18
- fludeoxyglucose-f18
- fludeoxyglucose-f18
- fludeoxyglucose, f-18
- fludeoxyglucose, f-18
- fluordeoxyglucose
- fluorine-18 fludeoxyglucose
- fluorine f 18 fluorodeoxyglucose
- fluorine f 18 fluorodeoxyglucose
- fluorodeoxyglucose
- fluorodeoxyglucose
- fluorodeoxyglucose f 18
- fluorodeoxyglucose f 18
- fluoro-d-glucose
- fluoro-d-glucose
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07278856 | Phase 1 | Apr 27, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07293247 | Phase 2 | Mar 14, 2026 | National Cancer Institute (NCI) |
| NCT06815029 | Phase 1 | Jan 2, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT07097363 | Phase 2 | Jan 1, 2026 | AbbVie, University of Washington |
| NCT07066709 | Phase 2 | Dec 31, 2025 | University of Wisconsin |
| NCT07285993 | Phase 2 | Dec 30, 2025 | Icahn School of Medicine at Mount Sinai |
| NCT07118176 | Phase 1 | Aug 1, 2025 | University of California, Los Angeles |
| NCT07087106 | Phase 4 | Jul 31, 2025 | Genzyme, Harvard University |
| NCT07089641 | Phase 1 | Jul 28, 2025 | University of California, Los Angeles |
| NCT07023861 | Early Phase 1 (Phase 1) | Jul 1, 2025 | Jiangnan University |
| NCT07023848 | Early Phase 1 (Phase 1) | Jul 1, 2025 | Jiangnan University |
| NCT07301801 | Early Phase 1 (Phase 1) | Jun 12, 2025 | Huazhong University of Science and Technology |
| NCT06956391 | Phase 2 | May 12, 2025 | — |
| NCT06820957 | Phase 2/Phase 3 (Phase 3) | Apr 15, 2025 | National Cancer Institute (NCI) |
| NCT06995976 | Early Phase 1 (Phase 1) | Mar 1, 2025 | Fujian Medical University |
| NCT06715020 | N/A | Dec 31, 2024 | Cancer Hospital of Yunnan provinceal, Peking University |
| NCT06717113 | Early Phase 1 (Phase 1) | Dec 15, 2024 | Peking University |
| NCT06502691 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Breast Cancer Research Foundation, University of Washington |
| NCT06630845 | N/A | Nov 30, 2024 | General Electric, Society of Abdominal Radiology, University of California, San Francisco |
| NCT06503146 | Phase 2 | Nov 17, 2024 | National Cancer Institute (NCI) |
Organizations
Research & Development (248)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 99 | 38 | 4 | 1996 |
| University of Pennsylvania | Academic/Hospital | 17 | 15 | 4 | 1999 |
| Cornell University | Academic/Hospital | 16 | 11 | 4 | 1996 |
| Stanford University | Academic/Hospital | 16 | 15 | 4 | 2006 |
| University of Washington | Academic/Hospital | 16 | 13 | 2 | 2005 |
| Mayo Clinic | Academic/Hospital | 13 | 11 | 4 | 2008 |
| National Institutes of Health (NIH) | Government | 12 | 4 | 4 | 1998 |
| Peking University | Academic/Hospital | 11 | 10 | 3 | 2022 |
| Washington University in St. Louis | Academic/Hospital | 11 | 7 | 4 | 1999 |
| University of California, Los Angeles | Academic/Hospital | 9 | 8 | 3 | 2007 |
| University of Texas at Houston | Academic/Hospital | 9 | 7 | 3 | 2004 |
| University of Toronto | Academic/Hospital | 9 | 7 | 3 | 2008 |
| Harvard University | Academic/Hospital | 8 | 5 | 4 | 2003 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 7 | 7 | 3 | 2013 |
| Case Western Reserve University | Academic/Hospital | 6 | 5 | 3 | 2004 |
| City of Hope National Medical Center | Academic/Hospital | 6 | 5 | 2 | 2007 |
| Johns Hopkins University | Academic/Hospital | 6 | 3 | 3 | 2004 |
| Ohio State University | Academic/Hospital | 6 | 5 | 3 | 2004 |
| University of Ottawa | Academic/Hospital | 6 | 5 | 3 | 2010 |
| Radboud University | Academic/Hospital | 5 | 3 | 2 | 2006 |
Marketing (49)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| 3d Imaging Drug Design & Development | For profit | MKTG | Oct 30, 2015 |
| Biomedical Research Foundation | Academic/Hospital | MKTG | May 1, 2015 |
| CPDC | For profit | MKTG | Oct 29, 2014 |
| Cardinal Health | Academic/Hospital | MKTG | Nov 13, 2015 |
| Columbia University | Academic/Hospital | MKTG | Apr 11, 2016 |
| Cornell University | Academic/Hospital | NDA2 | Aug 5, 2004 |
| Decatur Memorial Hospital | Academic/Hospital | MKTG | Oct 21, 2014 |
| Essential Isotopes, LLC | For profit | MKTG | Feb 5, 2014 |
| Feinstein Institute for Medical Research | Academic/Hospital | NDA2 | Aug 19, 2005 |
| Harvard University | Academic/Hospital | SYN | Oct 30, 2014 |
| Harvard University | Academic/Hospital | MKTG | Sep 25, 2014 |
| Hot Shots Nuclear Medicine | For profit | MKTG | Oct 30, 2014 |
| Houston Cyclotron | For profit | MKTG | Feb 14, 2013 |
| Isologic Innovative | For profit | MKTG | Oct 29, 2014 |
| Jubilant DraxImage Inc. | For profit | MKTG | Jun 23, 2015 |
| Jubilant Innovation Ltd. | For profit | MKTG | Jun 23, 2015 |
| Kettering Health Network | Academic/Hospital | MKTG | Oct 27, 2015 |
| Lantheus Medical Imaging | For profit | MKTG | Feb 4, 2014 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | MKTG | Dec 8, 2016 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | MKTG | Apr 23, 2015 |
| Midwest Medical Isotopes | For profit | MKTG | Nov 19, 2015 |
| NCM USA | For profit | MKTG | Jan 7, 2015 |
| Northland Nuclear Medicine | For profit | MKTG | Feb 4, 2015 |
| Nukemed | For profit | MKTG | Apr 22, 2015 |
| Pharmalogic Hldgs | For profit | MKTG | Feb 4, 2014 |
| Precision Nuclear | For profit | MKTG | Apr 7, 2015 |
| Queen Hamamatsu Pet Imaging Center | Academic/Hospital | MKTG | Aug 31, 2015 |
| Shertech Labs Llc | For profit | MKTG | Dec 18, 2014 |
| Siemens | For profit | MKTG | Feb 25, 2011 |
| Sofie | For profit | MKTG | Aug 31, 2015 |
| Spectron Mrc Llc | For profit | MKTG | Apr 22, 2015 |
| Stanford University | Academic/Hospital | MKTG | Sep 11, 2015 |
| State University of New York, Brooklyn | Academic/Hospital | NDA2 | Aug 19, 1994 |
| State University of New York, Brooklyn | Academic/Hospital | NDA | Aug 19, 1994 |
| The University of Texas, Dallas | Academic/Hospital | MKTG | Feb 6, 2020 |
| University of California, Los Angeles | Academic/Hospital | MKTG | Jun 27, 2013 |
| University of California, San Francisco | Academic/Hospital | MKTG | May 9, 2014 |
| University of Iowa | Academic/Hospital | MKTG | Aug 6, 2014 |
| University of Michigan | Academic/Hospital | SYN | Oct 29, 2014 |
| University of Michigan | Academic/Hospital | MKTG | Jul 17, 2015 |
| University of Pennsylvania | Academic/Hospital | MKTG | Oct 29, 2014 |
| University of Pennsylvania | Academic/Hospital | SYN | Aug 5, 2013 |
| University of Southern California | Academic/Hospital | MKTG | Dec 16, 2020 |
| University of Texas at Houston | Academic/Hospital | MKTG | Jan 13, 2014 |
| University of Utah | Academic/Hospital | MKTG | Jun 23, 2015 |
| University of Wisconsin | Academic/Hospital | MKTG | Dec 23, 2013 |
| University of Wisconsin | Academic/Hospital | MKTG | Dec 23, 2013 |
| Washington University in St. Louis | Academic/Hospital | MKTG | Feb 5, 2014 |
| Zevacor | For profit | MKTG | Oct 21, 2014 |